Indivior Plc - Company Profile
Powered by
All the data and insights you need on Indivior Plc in one report.
- Save hours of research time and resources with
our up-to-date Indivior Plc Strategy Report
- Understand Indivior Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Indivior Plc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectable for the treatment of opioid dependence, and buprenorphine-based injectable suspension, for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses buprenorphine-based products for substance use disorder; and cannabis disorder. Indivior offers products in the form of film, tablets, injectable suspension and nasal spray. It provides its products in the US, Australia, Malaysia, France, Italy; Spain, Germany, Canada, and the UK. Indivior is headquartered in Slough, England, the UK.
Indivior Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Opiod Dependence Drugs: | Subutex |
Suboxone (Sublingual Film/Sublingual Tablet) | Suboxone |
Subutex (Sublingual Tablet) | Sublocade |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, Indivior Inc. along with Indivior UK Limited entered into a settlement agreement with Actavis Laboratories UT to resolve patent disputes of Actavis's Abbreviated New Drug Application for generic buprenorphine and naloxone sublingual film. |
2023 | Corporate Changes/Expansions | In November, the company announced its plans to invest US$60 million in the Raleigh manufacturing plant. |
2023 | Contracts/Agreements | In October, the company secured an exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.’s portfolio of long-acting injectable formulations. |
Competitor Comparison
Key Parameters | Indivior Plc | AstraZeneca Plc | Vernalis R&D Ltd | Cassava Sciences Inc | GW Pharmaceuticals Ltd |
---|---|---|---|---|---|
Headquarters | United Kingdom | United Kingdom | United Kingdom | United States of America | United Kingdom |
City | Slough | Cambridge | Cambridge | Austin | Cambridge |
State/Province | Berkshire | England | England | Texas | England |
No. of Employees | 1,051 | 89,900 | - | 29 | - |
Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Graham Hetherington | Chairman | Executive Board | 2020 | 65 |
Mark Crossley | Chief Executive Officer; Director | Executive Board | 2020 | 54 |
Ryan Preblick | Director; Chief Financial Officer | Executive Board | 2020 | 48 |
Jeffrey Burris | Chief Legal Officer | Senior Management | 2021 | 52 |
Cynthia Cetani | Chief Compliance Officer; Chief Integrity Officer | Senior Management | 2018 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward